Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 18/20 | 0.62 |
| ▸ | EDNRA | P25101 | 2/20 | 0.54 |
| ▸ | EDNRB | P24530 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061454 | 0.87 | DHPS (0.83) | DHPS | |
| SCHEMBL4066788 | 0.87 | DHPS (0.85) | DHPSEDNRAEDNRB | |
| SCHEMBL5032725 | 0.84 | DHPS (0.59) | DHPS | |
| SCHEMBL2640202 | 0.84 | EDNRA (0.52) | DHPSEDNRAEDNRB | |
| SCHEMBL7209693 | 0.83 | DHPS (0.58) | DHPS | |
| SCHEMBL5039297 | 0.83 | DHPS (0.61) | DHPS | |
| SCHEMBL4060912 | 0.81 | DHPS (0.66) | DHPSEDNRAEDNRB | |
| SCHEMBL7979334 | 0.81 | DHPS (0.61) | DHPS | |
| Hydrochloric Acid SCHEMBL5035309 | 0.80 | DHPS (0.55) | DHPS | |
| SCHEMBL5041643 | 0.80 | DHPS (0.55) | DHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4737686-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-20100173919-A1 | PHARMACEUTICAL COMPOSITION USING ALISKIREN AND AVOSENTAN | NOVARTIS AG (CH) | 2010-07-08 | — | — | US | claimed |
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | SPEEDEL PHARMA AG (CH) | 2010-06-24 | — | — | US | claimed |
| US-20090005404-A1 | Pyridylsulfonamido pyrimidines for treating diabetic nephropathy | MANN JESSICA | 2009-01-01 | — | — | US | claimed |
| US-7402587-B2 | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists | SPEEDEL PHARMA AG (CH) | 2008-07-22 | — | — | US | claimed |
| EP-1938812-A1 | Pharmaceutical composition using aliskiren and avosentan | Speedel Pharma AG (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1924325-A2 | PYRIDYLSULFONAMIDYL-PYRIMIDINES FOR THE PREVENTION OF BLOOD VESSEL GRAFT FAILURE | Speedel Pharma AG (CH) | 2008-05-28 | — | — | EP | claimed |
| EP-1601361-B1 | PYRIDYLSULFONAMIDO PYRIMIDINES FOR TREATING DIABETIC NEPHROPATHY | SPEEDEL PHARMA AG (CH) | 2008-05-14 | — | — | EP | claimed |
| US-20070173520-A1 | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists | SPEEDEL PHARMA AG (CH) | 2007-07-26 | — | — | US | claimed |
| WO-2007031501-A2 | PYRIDYLSULFONAMIDYL-PYRIMIDINES FOR THE PREVENTION OF BLOOD VESSEL GRAFT FAILURE | SPEEDEL PHARMA AG (CH) | 2007-03-22 | — | — | WO | claimed |
| EP-1185525-B1 | 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | claimed |
| EP-1601361-A2 | PYRIDYLSULFONAMIDO PYRIMIDINES FOR TREATING DIABETIC NEPHROPATHY | Speedel Pharma AG (CH) | 2005-12-07 | — | — | EP | claimed |
| WO-2005113543-A1 | CRYSTALLINE FORMS OF A PYRIDINYL-SULFONAMIDE AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | SPEEDEL PHARMA AG (CH) | 2005-12-01 | — | — | WO | claimed |
| EP-1595880-A1 | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists | Speedel Pharma AG (CH) | 2005-11-16 | — | — | EP | claimed |
| WO-2004078104-A2 | PYRIDYLSULFONAMIDO PYRIMIDINES FOR TREATING DIABETIC NEPHROPATHY | SPEEDEL PHARMA AG (CH) | 2004-09-16 | — | — | WO | claimed |
| EP-1454625-A1 | Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies | Speedel Development AG (CH) | 2004-09-08 | — | — | EP | claimed |
| US-6521631-B2 | N-(6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4 -yl)) 5-isopropyl-pyridine-2-sulfonamide; treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction. | HOFFMANN-LA ROCHE INC. | 2003-02-18 | — | — | US | claimed |
| US-20020137933-A1 | Heterocyclic sulfonamides | BREU VOLKER (DE) | 2002-09-26 | — | — | US | claimed |
| EP-1185525-A1 | 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-13 | — | — | EP | claimed |
| WO-2000052007-A1 | 4-HETEROCYCLYSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173919-A1 | PHARMACEUTICAL COMPOSITION USING ALISKIREN AND AVOSENTAN | AGTR1, APLNR, REN | DHPS 4219/4885EDNRA 43/4885EDNRB 80/4885 |
| US-20020137933-A1 | Heterocyclic sulfonamides | ECE1, EDNRA, EDNRB | DHPS 557/4885EDNRA 2/4885EDNRB 3/4885 |
| US-20090005404-A1 | Pyridylsulfonamido pyrimidines for treating diabetic nephropathy | PDXK, REN, C5 | DHPS 86/4885EDNRA 205/4885EDNRB 76/4885 |
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | PDXK, CBS, C1S | DHPS 93/4885EDNRA 395/4885EDNRB 137/4885 |
| US-20070173520-A1 | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists | EDNRB, EDNRA, AGTR2 | DHPS 2081/4885EDNRA 2/4885EDNRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.